Halozyme Therapeutics
HALO
#2402
Rank
C$10.28 B
Marketcap
C$87.49
Share price
0.60%
Change (1 day)
29.83%
Change (1 year)

Halozyme Therapeutics (HALO) - P/B ratio

P/B ratio as of December 2025 : 14.9

According to Halozyme Therapeutics's latest financial reports the company has a price-to-book ratio of 6.02342.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Halozyme Therapeutics - P/B ratio (from 2004 to 2025)

P/B ratio by year

Year P/B ratio Change
2025-12-31N/A-100%
2024-12-3116.8-71.11%
2023-12-3158.328.57%
2022-12-3145.357.64%
2021-12-3128.7-24.8%
2020-12-3138.244.71%
2019-12-3126.4210.5%
2018-12-318.51-38.54%
2017-12-3113.8-135.14%
2016-12-31-39.4-176.26%
2015-12-3151.676.05%
2014-12-3129.3-134.16%
2013-12-31-85.9-654.8%
2012-12-3115.5-82.89%
2011-12-3190.5131.13%
2010-12-3139.1-49.79%
2009-12-3178.0162.89%
2008-12-3129.7209.28%
2007-12-319.59-60%
2006-12-3124.0298.07%
2005-12-316.02-17.52%
2004-12-317.30
2003-12-31N/A
2002-12-31N/A

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
MannKind Corp
MNKD
-39.1-363.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
37.8 154.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
1.33-91.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
1.59-89.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
1.40-90.60%๐Ÿ‡ซ๐Ÿ‡ท France
Johnson & Johnson
JNJ
6.15-58.63%๐Ÿ‡บ๐Ÿ‡ธ USA